Compare NWPX & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWPX | HROW |
|---|---|---|
| Founded | 1966 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.9M | 1.0B |
| IPO Year | 1996 | 2008 |
| Metric | NWPX | HROW |
|---|---|---|
| Price | $84.56 | $30.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $107.67 | $62.25 |
| AVG Volume (30 Days) | 109.8K | ★ 637.4K |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.71 | ★ 71.43 |
| EPS | ★ 4.55 | N/A |
| Revenue | ★ $526,003,000.00 | N/A |
| Revenue This Year | $16.79 | $28.13 |
| Revenue Next Year | N/A | $56.02 |
| P/E Ratio | $19.22 | ★ N/A |
| Revenue Growth | ★ 6.79 | N/A |
| 52 Week Low | $55.43 | $25.76 |
| 52 Week High | $152.03 | $54.98 |
| Indicator | NWPX | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 34.08 | 52.98 |
| Support Level | $80.54 | $28.54 |
| Resistance Level | $89.24 | $35.32 |
| Average True Range (ATR) | 3.88 | 1.96 |
| MACD | -0.24 | 0.50 |
| Stochastic Oscillator | 11.45 | 59.98 |
NWPX Infrastructure Inc is a manufacturer of water-related infrastructure products, and operates in two segments, Water Transmission Systems (WTS), operating as the Northwest Pipe Company brand, and Precast Infrastructure and Engineered Systems (Precast), which includes the brands NWPX Geneva and NWPX Park. WTS manufactures large-diameter, high-pressure steel pipeline systems for use in water infrastructure applications, which are related to drinking water systems. Precast manufactures stormwater and wastewater technology products, high-quality precast and reinforced concrete products, including reinforced concrete pipe (RCP), manholes, box culverts, vaults, and catch basins, pump lift stations, oil water separators, biofiltration units, and other environmental and engineered solutions.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.